Abstract
PurposeTo investigate the outcome of phacoemulsification in selective laser trabeculoplasty (SLT)-treated eyes.MethodsThis retrospective study included patients who had open angle glaucoma (OAG) with previous SLT who underwent phacoemulsification. We evaluated intraocular pressure (IOP), length of glaucoma control without treatment, and antiglaucoma medication or surgery. SLT-treated eyes that did not receive phacoemulsification were retrospectively chosen as a control. We investigated factors related to outcome of phacoemulsification by multivariate analysis.Results42 eyes with previous SLT that underwent phacoemulsification and 40 controls were retrospectively evaluated. Phacoemulsification was performed 52 ± 15 months after SLT. After a mean follow-up of 74 ± 21 months, mean IOP was significantly decreased in the phaco group by 2.2 ± 2.7 mmHg (p < 0.001). In the SLT group, mean IOP was decreased by 0.8 ± 2.8 mmHg (p < 0.001). 9 eyes (16.7%) in the phaco group and 11 eyes (19.0%) of the SLT group needed topical treatment, and no eye needed glaucoma surgery in both groups. The factor related to success was higher baseline IOP (p = 0.002).ConclusionPrior SLT didn’t negatively influence phacoemulsification in patients with OAG. Phacoemulsification lowered IOP effectively and safely in OAG patients who were treated with SLT.
Highlights
Glaucoma is a progressive neurodegenerative optic neuropathy marked by the morphological changes of optic disc and results in an irreversible visual field defect by loss of retinal ganglion cells, leading to blindness [1, 2]
In the Selective laser trabeculoplasty (SLT) group, mean intraocular pressure (IOP) was decreased by 0.8 ± 2.8 mmHg (p < 0.001). 9 eyes (16.7%) in the phaco group and 11 eyes (19.0%) of the SLT group needed topical treatment, and no eye needed glaucoma surgery in both groups
Phacoemulsification lowered IOP effectively and safely in open angle glaucoma (OAG) patients who were treated with SLT
Summary
Glaucoma is a progressive neurodegenerative optic neuropathy marked by the morphological changes of optic disc and results in an irreversible visual field defect by loss of retinal ganglion cells, leading to blindness [1, 2]. Selective laser trabeculoplasty (SLT) utilizes 532 nm, frequency-doubled, Q-switched, neodymium-doped yttrium aluminum garnet (Nd:YAG) laser that aims pigmented trabecular meshwork (TM) cells without damaging adjacent structures [4,5,6]. SLT causes less damage than unlike argon laser trabeculoplasty (ALT) and no coagulative effects on TM [8, 9]. SLT has been established for over a decade as a successful treatment for IOP reduction in open angle glaucoma (OAG) patients [10]. It is safe and potentially repeatable and can be considered in those patients who cannot tolerate drops or whose IOP is not controlled with drops sufficiently well
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
